Extract
Fibrotic interstitial lung diseases (ILDs) are chronic and often progressive conditions resulting in substantial impact on morbidity, health-related quality of life (HRQoL), and health system costs. Ambulatory oxygen (AO) used during routine daily activities could lead to improved exercise performance, reduced symptoms and improved mobility in daily life. A UK prospective, multicentre, mixed method, randomised controlled crossover trial in patients with fibrotic ILD (AmbOx trial: NCT02286063), the first study on AO effects in daily life, reported improved HRQoL after 2 weeks of AO compared to no intervention, when measured by the King's Brief ILD (K-BILD) questionnaire [1–3]. Although AO is used in ILD, evidence supporting its health-economic impact is absent. Here, we evaluate the cost-effectiveness of AO in patients with ILD, using data collected alongside the AmbOx Trial.
Abstract
Ambulatory oxygen may be cost-effective in improving quality of life in fibrotic lung disease. To be more conclusive, we need to understand societal willingness to pay for quality of life improvements and whether improvements are sustained. http://bit.ly/2pAiBJi
Acknowledgements
The study was supported by the NIHR Biomedical Research Unit at Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. Members of the DMC: Joanna Porter, Chair; Sunita Rehal, independent statistician; John S. Wort. Members of the TSC: Stephen Durham, Vicky Tsipouri, Ira Jakupovic, Elisabetta Renzoni, Dina Visca, Voon Ong, Arnab Datta. We thank John Tayu Lee for providing input into the design of the economic evaluation component of the study. We also thank the RBH Research and Finance Office for their help in organising and supporting the infrastructure needed for the study, in particular Patrick Petterson and Alla Kashif. The AmbOx study is funded in full by the Research for Patient Benefit Programme National Institute for Health Research (Ref: PB-PG-0712-28073). Additional infrastructure support for the study is being provided by the Royal Brompton NIHR-funded Biomedical Research Unit.
Footnotes
Support statement: This manuscript presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0712-28073). The funder has no role in the trial design, collection, management, analysis or interpretation of data, writing of reports or submission for publication. Jennifer Whitty is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) East of England. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: J.A. Whitty reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study.
Conflict of interest: J. Rankin reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study.
Conflict of interest: D. Visca reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study.
Conflict of interest: V. Tsipouri reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study.
Conflict of interest: L. Mori reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study.
Conflict of interest: L. Spencer reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study.
Conflict of interest: H. Adamali has nothing to disclose.
Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R and D and UCB, and has received consultancy or speakers fees from Apellis, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R and D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB.
Conflict of interest: N.S. Hopkinson reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study.
Conflict of interest: S.S. Birring reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study; fees (to Kings College Hospital) for using KBILD from Boehringer Ingleheim, Roche, Galapogos and Novartis, outside the submitted work.
Conflict of interest: M. Farquhar reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study.
Conflict of interest: A.U. Wells reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study; personal fees for lectures and advisory board work from Boehringer Ingelheim, Roche and Bayer, outside the submitted work.
Conflict of interest: P. Sestini reports grants from Research for Patient Benefit Programme National Institute for Health Research (Ref: PB-PG-0712-28073), and Royal Brompton and Harefield NHS Foundation and Trust, during the conduct of the study.
Conflict of interest: E.A. Renzoni reports grants from Research for Patient Benefit Programme National Institute for Health Research (ref: PB-PG-0712-28073), during the conduct of the study; personal fees for lectures and advisory board work from Boehringer Ingelheim and Roche, personal fees for lectures from Mundipharma, outside the submitted work.
- Received January 25, 2019.
- Accepted October 14, 2019.
- Copyright ©ERS 2020
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org